Nationally Recognized Gynecologic Oncologist Brings His Expertise to MSU “to take excellent care of patients”

<p><a href="https://healthcare.msu.edu/news/field-announce.html">Dr. Field</a> is a nationally recognized gynecologic oncologist. He brings more than 15 years of oncology experience to Mid-Michigan. Dr. Field specializes in minimally invasive surgery, open debulking of ovarian cancer, chemotherapy, and hormone therapy treatments for women with gynecologic cancers, including ovarian and endometrial cancer. Since 2012, he has served as principal investigator for Gynecologic Oncology Group, NRG Oncology Clinical Trials, which is responsible for improving and expanding cancer diagnosis and treatment. He is assistant professor and director of the Division of Gynecologic Oncology in the Department of <a href="https://obgyn.msu.edu/">Obstetrics, Gynecology, and Reproductive Biology</a> in the College of Human Medicine at Michigan State University. </p><p>“Gynecologic oncology has a bit of a name problem,” says Field. “We're basically specialists in women's cancer. We treat women with cancers of the reproductive tract and sometimes benign problems as well, so problems with the uterus, the cervix, the ovaries, and the tubes. We do both surgery and chemotherapy and coordinate radiation oncology care for women with gynecologic cancer. We're a bit like the primary care doctor for women with those types of cancers.”</p><p>What attracted Dr. Field to MSU?</p><p>“The biggest thing that a gynecologic oncologist likes to do is be busy taking care of patients, and this area has been without a gynecologic oncologist. Everyone was really enthusiastic about being able to offer those services in this area. My main goal is to take excellent care of patients and do excellent surgery and care for patients through the life cycle after their diagnosis with a cancer.”</p><p>Dr. Field says there have been “amazing breakthroughs” in the last three years.</p><p>“We'd gone through sort of a 10-year dry period with not a lot of new treatments, and in the last three years, we've got a whole new class of treatments for patients with ovari